Gaudium IVF & Women Health IPO Day 1: Subscription at 0.27x, GMP Rises 10.76% | Live Updates

Posted by : Neeraj Pandey | Fri Feb 20 2026

The Gaudium IVF & Women Health IPO GMP is ₹8.5 as of 20th February 2026. It is a book-building issue IPO of ₹165.00 crores. This is an entirely fresh issue of 1.14 crore shares. The issue will be listed on BSE and NSE on its tentative listing date, 27th February 2026. The face value of Gaudium IVF & Women Health IPO shares is ₹10 per share, and the IPO price band is ₹75 to ₹79 per share. Retail investors can bid for a minimum of 1 lots of 189 shares worth ₹14,931. Scroll down to check the Gaudium IVF & Women Health IPO GMP and subscription details.

Table of Contents

Gaudium IVF & Women Health IPO GMP Grey Market Premium

As mentioned earlier, the Gaudium IVF & Women Health IPO GMP currently stands at ₹8.5 per share. Thus, the estimated listing price would be at ₹87.5. This indicates that the estimated listing gain in this IPO could be 10.76%. Explore the table for Gaudium IVF & Women Health IPO GMP updates.

GMP DATE	IPO Price	GMP Price	Estimated Listing Price	Estimated Gain
20-2-2026	₹79.00	₹8.5	₹87.5	10.76%
19-2-2026	₹79.00	₹8.5	₹87.5	10.76%
18-2-2026	₹79.00	₹12.00	₹91.00	15.19%
17-2-2026	₹79.00	₹15.00	₹94.00	18.99%
16-2-2026	₹79.00	₹0.00	₹79.00	0.00%
15-2-2026	₹79.00	₹0.00	₹79.00	0.00%
14-2-2026	₹79.00	₹0.00	₹79.00	0.00%
13-2-2026	₹79.00	₹0.00	₹79.00	0.00%

Note: GMP details are subject to change based on market conditions and fluctuations. Check the live Gaudium IVF & Women Health IPO GMP status at Univest.

Click and Sign Up to Get Live Updates on Gaudium IVF & Women Health IPO GMP Status

Gaudium IVF & Women Health IPO Subscription Status

As of now, the Gaudium IVF & Women Health IPO has been subscribed to 0.27 times. Of these, 0.44 times are subscribed by retail investors, 0.23 times by non-institutional investors, and 0.00 times by QII (Qualified Institutional Investors).

The healthy subscription status indicates that investors are expecting higher returns at the time of Gaudium IVF & Women Health’ IPO listing on 27th February 2026. Gaudium IVF & Women Health also has a positive outlook behind the fresh issue of 1.14 crore shares, which will raise around Rs 165.00 crores.

Note: GMP details are subject to change based on market conditions and fluctuations. Check the live Gaudium IVF & Women Health IPO Subscription status at Univest.

Click and Sign Up to Get Live Updates on Gaudium IVF & Women Health IPO Subscription Status

Gaudium IVF & Women Health IPO Details

IPO Allotment Date	25th February 2026
IPO Open Date	20th January 2026
IPO Close Date	24th February 2026
Refund Initiation	25th February 2026
Issue Size	2,08,86,200 shares(agg. up to ₹165 Cr)
Fresh Issue	1,13,92,500 shares(agg. up to ₹90 Cr)
Offer for Sale	94,93,700 shares of ₹5(agg. up to ₹75 Cr)
Face Value	₹5 per share
Lot Size	189 Shares
Issue Price	₹75 to ₹79 per share
Issue Type	Bookbuilding IPO
Listing At	BSE NSE
Listing Date	27th February 2026

Also Read: Gaudium IVF & Women Health IPO GMP & Review: Apply or Avoid?

Explanation

Gaudium IVF & Women Health IPO: Gaudium IVF & Women Health IPO Limited has declared an issue price band of ₹75 to ₹79 per share. With this IPO, the company allows retail investors to bid for at least 1 lots of 189 shares, each worth ₹14,931. The face value of Gaudium IVF & Women Health IPO Limited shares is ₹5 per share. The shares of Gaudium IVF & Women Health IPO Limited will be listed on BSE and NSE on its tentative listing day, 27th February 2026. Scroll down to check GMP updates and Gaudium IVF & Women Health IPO reviews.

About Gaudium IVF & Women Health Ltd.

Gaudium IVF & Women Health Incorporated in March 2015, Gaudium IVF and Women Health Limited have been involved in In Vitro Fertilisation (IVF) procedures across India and have extended their services to several states using a hub-and-spoke model of operation. The firm has more than thirty locations, consisting of seven hubs (centres) and twenty-eight spokes. The firm has formed a strategic alliance with Infertility Experts, referred to as Spokes, to attain the common goal of creating awareness about Assisted Reproductive Technology (ART) and In Vitro Fertilisation (IVF) procedures. The firm provides services to patients belonging to different nations, such as Canada, the United Kingdom, the United States of America, Kenya, South Africa, and Oman.

Gaudium IVF & Women Health Limited Financials

The company’s financial analysis is essential before applying for the Gaudium IVF & Women Health IPO. See the table for Gaudium IVF & Women Health Limited’s financials.

Year Ended	30th Sep 2025 (in cr.)	31st March 2025 (in cr.)	31st March 2024 (in cr.)	31st March 2023 (in cr.)
Assets	106.62	88.51	51.01	36.63
Revenue	49.75	70.96	48.15	44.26
Profit After Tax	12.51	19.13	10.32	13.53
EBITDA	18.95	28.63	19.27	20.07
Net Worth	58.85	46.30	26.99	22.73
Reserves and Surplus	28.16	15.60	26.00	21.74
Total Borrowings	22.51	18.93	15.73	9.78

Explanation

Gaudium IVF & Women Health Limited’s revenue increased by 47.37% from ₹48.15 crores in March 2024 to ₹70.96 crores in March 2025. Moreover, the company’s PAT increased by 85.36% from ₹10.32 crores in March 2024 to ₹19.13 crores in March 2025.

Gaudium IVF & Women Health IPO Objectives

The primary aim of the Gaudium IVF & Women Health IPO is to raise ₹165.00 crores. On the other hand, Fractal Analytics has decided to utilise these funds in different ways.

To fund capital expenditure towards the establishment of the New IVF Centres of the Company.
To General Corporate Purposes
To Repayment/pre-payment, in full or in part, of certain outstanding loans availed by the Company.

Gaudium IVF & Women Health IPO Registrar

Bigshare Services Private Limited is the registrar for the Gaudium IVF & Women Health IPO, awaiting the allotment process and initiating refunds. For any queries regarding the Gaudium IVF & Women Health allotment and refund, you can contact Bigshare Services Private Limited at ipo@bigshareonline.com or at +91-22-6263 8200.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

Gaudium IVF & Women Health IPO Review

The Gaudium IVF & Women Health IPO has gained neutral ratings from industry experts, brokers, and institutional investors. Gaudium IVF & Women Health Limited’s revenue increased by 47.37% from ₹48.15 crores in March 2024 to ₹70.96 crores in March 2025. Moreover, the company’s PAT increased by 85.36% from ₹10.32 crores in March 2024 to ₹19.13 crores in March 2025.Most analysts recommend applying for this IPO to diversify your investment portfolio. However, we’re waiting for additional ratings to get a clearer picture and will keep posting them to deliver real-time insights. Until then, you can explore the company’s technical analysis to know whether you should apply for the Gaudium IVF & Women Health IPO or not.

Key Indicators	Value
PE Ratio (Price-to-Earnings)	25.36
EPS (Earnings Per Share)	3.12
RoNW	21.34%
ROCE	21.03%
ROE	21.25%
EBITDA Margin	38.29%
Price to Book Value	–
Market Capitalisation	₹575.02 Cr

The P/E ratio of Gaudium IVF & Women Health Limited shares is 25.36, and its Earnings Per Share (EPS) stands at 3.12. Thus, the Gaudium IVF & Women Health IPO can deliver gains on its tentative listing date, 27th February 2026.

Note: The data, as mentioned above, is taken from authentic sources and highlights pre-issue information. The PE ratio and EPS of Gaudium IVF & Women Health Limited are subject to change after the IPO. Explore the table below to get post-issue updates on these two metrics.

Indicators	Pre-IPO	Post-IPO
PE Ratio	25.36	22.99
EPS	3.12	3.44

FAQs on Gaudium IVF & Women Health IPO

What is the Gaudium IVF & Women Health IPO GMP?

Currently, on 20th February 2026, the Gaudium IVF & Women Health IPO GMP (Grey Market Premium) stands at ₹8.5. This indicates that the estimated listing price could be ₹87.5 per share.

What is the issue price of the Gaudium IVF & Women Health IPO?

The Gaudium IVF & Women Health IPO issue price band is set at ₹75.00 to ₹79.00 per share. Retail investors can apply for a minimum of 1 lots, each consisting of 189 shares, worth ₹14,931. Moreover, HNIs are required to bid for a minimum of 14 lots (189 shares) worth ₹14,931.

Who is the registrar of the Gaudium IVF & Women Health IPO?

Disclaimer: The above information is compiled from authentic sources and is just for informational purposes. To have detailed information about the Gaudium IVF & Women Health IPO, download the Gaudium IVF & Women Health IPO RHP and Gaudium IVF & Women Health IPO DRHP. Conduct your research before investing in IPOs to avoid significant losses. You can also consult your financial advisor.